HUP0103691A3 - Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them - Google Patents

Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them

Info

Publication number
HUP0103691A3
HUP0103691A3 HU0103691A HUP0103691A HUP0103691A3 HU P0103691 A3 HUP0103691 A3 HU P0103691A3 HU 0103691 A HU0103691 A HU 0103691A HU P0103691 A HUP0103691 A HU P0103691A HU P0103691 A3 HUP0103691 A3 HU P0103691A3
Authority
HU
Hungary
Prior art keywords
microadenomas
adhd
pyrido
parkinson
disease
Prior art date
Application number
HU0103691A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HUP0103691A2 publication Critical patent/HUP0103691A2/hu
Publication of HUP0103691A3 publication Critical patent/HUP0103691A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0103691A 1998-09-21 1999-09-03 Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them HUP0103691A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (2)

Publication Number Publication Date
HUP0103691A2 HUP0103691A2 (hu) 2002-02-28
HUP0103691A3 true HUP0103691A3 (en) 2003-01-28

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103691A HUP0103691A3 (en) 1998-09-21 1999-09-03 Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them

Country Status (38)

Country Link
US (2) US6300329B1 (hu)
EP (1) EP1115402A1 (hu)
JP (1) JP2002526448A (hu)
KR (3) KR100468340B1 (hu)
CN (1) CN1319013A (hu)
AP (1) AP1456A (hu)
AR (1) AR029739A1 (hu)
AU (1) AU760230B2 (hu)
BG (1) BG105445A (hu)
BR (1) BR9913975A (hu)
CA (1) CA2344670A1 (hu)
CO (1) CO5140075A1 (hu)
CZ (1) CZ20011006A3 (hu)
DZ (1) DZ2894A1 (hu)
EA (2) EA200301063A1 (hu)
EE (1) EE200100179A (hu)
GE (1) GEP20033081B (hu)
GT (1) GT199900154A (hu)
HN (1) HN1999000146A (hu)
HR (1) HRP20010209A2 (hu)
HU (1) HUP0103691A3 (hu)
ID (1) ID28028A (hu)
IL (2) IL141507A0 (hu)
IS (1) IS5852A (hu)
MA (1) MA26690A1 (hu)
MY (1) MY127939A (hu)
NO (1) NO20011409L (hu)
NZ (1) NZ509855A (hu)
OA (1) OA11653A (hu)
PA (1) PA8482001A1 (hu)
PE (1) PE20001084A1 (hu)
PL (1) PL346904A1 (hu)
SK (1) SK3592001A3 (hu)
TN (1) TNSN99177A1 (hu)
TR (2) TR200101357T2 (hu)
TW (1) TW518225B (hu)
WO (1) WO2000016777A1 (hu)
YU (1) YU21701A (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
WO1995034555A1 (en) * 1994-06-14 1995-12-21 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
NO20011409D0 (no) 2001-03-20
BR9913975A (pt) 2001-06-19
IL164839A0 (en) 2005-12-18
ID28028A (id) 2001-05-03
EE200100179A (et) 2002-10-15
CA2344670A1 (en) 2000-03-30
GT199900154A (es) 2001-03-06
US20010034347A1 (en) 2001-10-25
AR029739A1 (es) 2003-07-16
KR20010075222A (ko) 2001-08-09
HUP0103691A2 (hu) 2002-02-28
TNSN99177A1 (fr) 2005-11-10
WO2000016777A1 (en) 2000-03-30
IL141507A0 (en) 2002-03-10
GEP20033081B (en) 2003-10-27
IS5852A (is) 2001-02-20
PE20001084A1 (es) 2000-10-18
DZ2894A1 (fr) 2003-12-15
EA200100204A1 (ru) 2001-08-27
CN1319013A (zh) 2001-10-24
AU760230B2 (en) 2003-05-08
TR200402083T2 (tr) 2004-10-21
US6300329B1 (en) 2001-10-09
AP2001002102A0 (en) 2001-03-31
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
PA8482001A1 (es) 2000-05-24
PL346904A1 (en) 2002-03-11
OA11653A (en) 2004-12-08
EP1115402A1 (en) 2001-07-18
AP1456A (en) 2005-09-30
SK3592001A3 (en) 2001-12-03
MA26690A1 (fr) 2004-12-20
TW518225B (en) 2003-01-21
EA200301063A1 (ru) 2004-12-30
CO5140075A1 (es) 2002-03-22
KR100468340B1 (ko) 2005-01-27
HN1999000146A (es) 2000-11-11
YU21701A (sh) 2004-07-15
HRP20010209A2 (en) 2002-04-30
BG105445A (en) 2001-12-29
MY127939A (en) 2007-01-31
KR20040054752A (ko) 2004-06-25
KR20030088512A (ko) 2003-11-19
NO20011409L (no) 2001-03-28
US6608064B2 (en) 2003-08-19
TR200101357T2 (tr) 2001-08-21
NZ509855A (en) 2003-04-29
AU5383199A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
HUP0103691A3 (en) Use of pyrido[1,2a]pyrazine derivatives for the treatment of parkinson's disease, adhd and microadenomas and medicaments containing them
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
EP0718287A3 (de) Piperazinderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendungen und Verfahren zu ihrer Herstellung
CZ20011652A3 (cs) Farmaceutický přípravek zahrnující moxifloxacin, způsob výroby a použití tohoto přípravku
HRP970450B1 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or diagnostic agents and drugs containing them
HUP0002718A3 (en) Piperazine derivatives, process for their preparation and medicaments containing the same
HUP9802807A3 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives, their use, production thereof and medicaments containing the same
NZ330360A (en) 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
PL332643A1 (en) 1h-pyrido-[3,4-b]-indolo-4-carboxyamidic derivatives, their production and application in medical treatment
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
HUP0104033A3 (en) 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
SI0810206T1 (en) Substituted 2-naphthoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
AU2141695A (en) Imidazo{1,2-a}pyrazine-4-one derivatives, preparation thereof and drugs containing same
PL346165A1 (en) Biphenylsulfonyl-substituted imidazole derivatives, their preparation process, their use as a drug or diagnostic agent and drug containing them
HRP970424B1 (en) Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them
IL132985A0 (en) 3-Substituted pyrido ¬3'4':4,5¾thieno ¬2,3-d¾pyrimidine derivatives and production and use of the same
HRP970294B1 (en) Substituted 1-naphtoylguanidines, process for their preparation, their use as medicament or diagnostic agent and medicaments containing them
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
HK127294A (en) Use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo [4,5-d] azepin for the preparation of a medicament for the treatment of Parkinson's disease, or of Parkinsonism
HK1039574A1 (zh) 治療帕金森氏病、adhd和微腺瘤的藥物試劑

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees